Home › Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea
 

Keywords :   


Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea

2015-09-08 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & SEOUL, South Korea First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orSamsung BioepisMedia:Jamyung Cha, (82) 32-455-6137orInvestors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in korea samsung approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
01.07Hurricane Beryl Graphics
01.07Hurricane Beryl Public Advisory Number 11A
01.07Summary for Hurricane Beryl (AT2/AL022024)
01.07Atlantic Tropical Weather Outlook
01.07Eastern North Pacific Tropical Weather Outlook
01.07Tropical Depression Chris Graphics
01.07Tropical Depression Chris Public Advisory Number 3A
01.07Union expected to call off Port Talbot strike action
More »